Evaluation of the Effect of Ionic Plasma Cluster Technology on the Improvement of Symptoms in Patients with COVID-19

Document Type : Original Article(s)

Authors

1 Assistant Professor of Infectious Disease, North Khorasan University of Medical Sciences, Bojnurd, Iran

2 BS of Nurse in Imam Hasan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran

3 Department of Medical Physics, School of Medicine,Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

4 Assistant Professor of Medical Physics and Radiology, North Khorasan University of Medical Sciences, Bojnurd, Iran

Abstract

Background: Fever, gastrointestinal symptoms, lethargy and weakness, headache, shortness of breath, and cough are usually clinical symptoms of COVID-19. This study aimedto investigate the effect of plasma cluster in improving the clinical symptoms of patients with COVID-19.
Methods: This study was a double-blind clinical trial that was conducted on patients with COVID-19at Imam Hassan (AS) Bojnurd Hospital. In the intervention group, the plasma clusters device was turned on continuously for 8 hours and then turned off. In the control group, the device was placed in the room, and the ionization part of the device was removed from the circuit. Patients were monitored for five days after the intervention in terms of improvement of clinical symptoms. Data analysis was done with T, χ2, and variance tests in repeated measures.
Findings: The results showed that fever on the first day and weakness and lethargy on the first and third days of the disease showed a significant decrease compared to the beginning. Other clinical symptoms of the patient did not show any significant difference in the two groups. Also, the clinical symptoms showed significant changes in the improvement of the symptoms of COVID-19 in the intervention group compared to the control group. However, there was no significant difference in body temperature between the two groups.
Conclusion: Therefore, along with routine treatments, the cold plasma device can be helpful as an auxiliary factor in improving patients' symptoms and treating them faster.

Highlights

Mohamad Reza Taghavi: Google Scholar 

Salar Poorbarat: Google Scholar

Mohamad Amin Younessi Heravi: Google Scholar

Keywords

Main Subjects

References

  1. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009; 7(6): 439-50.
  2. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020, 27(3): 325-8.
  3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
  4. Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Eur J Clin Invest 2020; 50(3): e13209.
  5. Wu Z, Mcgoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323)13(: 1239-42.‏
  6. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 2020; 395(10224): e35-e36.
  7. Centers for Disease Control and Prevention. Information for Clinicians on Therapeutic Options for COVID-19 Patients. Coronavirus Disease 2019 (COVID-19); 2020.
  8. Zhang Q, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol 2020; 92)6(: 540-5.
  9. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020; 19(3): 149-50.
  10. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect 2020; 22(2): 74-79.
  11. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr 2020; 16(3): 223-31.
  12. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res 2020; 7(1): 11.
  13. Smirnov BM. Cluster plasma. Phys-Usp 2000; 43(5): 453.
  14. Kolarž P, Gaisberger M, Madl P, Hofmann W, Ritter M, Hartl A. Characterization of ions at Alpine waterfalls. Atmos Chem Phys 2012; 12(8): 3687-97.
  15. Jiang S-Y, Ma A, Ramachandran S. Negative air ions and their effects on human health and air quality improvement. Int J Mol Sci 2018; 19(10): 2966.
  16. Gürsoy E, Saglam HY, Yavuz NŞ. Experiences of intensive care nurses working with patients with COVID-19: A qualitative study in Turkey. Nursing Practice Today 2023; 10(2): 124-37.‏
  17. Xia T, Kleinheksel A, Lee EM, Qiao Z, Wigginton KR, Clack HL. Inactivation of airborne viruses using a packed bed non-thermal plasma reactor. J Phys D Appl Phys 2019; 52(25): 255201.
  18. Digel I, Artmann AT, Nishikawa K, Cook M, Kurulgan E, Artmann G. Bactericidal effects of plasma-generated cluster ions. Med Biol Eng Comput 2005; 43(6): 800-7.
  19. Nishikawa K, Nojima H. Air purification effect of positively and negatively charged ions generated by discharge plasma at atmospheric pressure. Jpn J Appl Phys 2001; 40(8A): L835.
  20. Maloney MJ, Wray BB, DuRant RH, Smith L, Smith L. Effect of an electronic air cleaner and negative ionizer on the population of indoor mold spores. Ann Allergy 1987; 59(3): 192-4.
  21. Verma SS. Fighting COVID-19 with Non-Thermal Plasma Technology. The Indian Practitioner 2020; 73(7): 42-5.
  22. Wenzel, T, Carvajal Berrio DA, Reisenauer C, Layland S, Koch A, Wallwiener D, et al. Trans-mucosal efficacy of non-thermal plasma treatment on cervical cancer tissue and human cervix uteri by a next generation electrosurgical argon plasma device. Cancers (Basel) 2020, 12(2): 267.
  23. Chen Z, Bai F, Jonas SJ, Wirz RE. Cold atmospheric plasma for addressing the COVID‐19 pandemic. Plasma Process Polym 2022; 19(9): 2200012.‏
  24. Han I, Mumtaz S, Choi EH. Nonthermal Biocompatible Plasma Inactivation of Coronavirus SARS-CoV-2: Prospects for Future Antiviral Applications. Viruses 2022; 14(12): 2685.‏
  25. Chen Z, Garcia Jr G, Arumugaswami V, Wirz RE. Cold atmospheric plasma for SARS-CoV-2 inactivation. Phys Fluids (1994) 2020; 32(11): 111702.
Journal of Isfahan Medical School
Volume 42, Issue 771
3rd Week, August
July and August 2024
Pages 489-496

Files

History

  • Receive Date: 07 February 2024
  • Accept Date: 03 September 2024

Share

How to cite

Statistics